The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Molecular Pathways in Invasive Bladder Cancer: New Insights Into Mechanisms, Progression, and Target Identification
Abstract
Papillary and invasive cancers of the urinary bladder appear to evolve and progress through distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and these tumors are generally characterized by alterations in the p53 and retinoblastoma (RB) pathways that normally regulate the cell cycle by interacting with the Ras–mitogen activated protein kinase signal transduction pathway. Tumor angiogenesis further contributes to the neoplastic growth by providing a constant supply of oxygen and nutrients. Distinct epigenetic and genetic events characterize the interplay between the molecules involved in these pathways, thus affording their use as indicators of prognosis. Efforts are now underway to construct molecular panels comprising multiple markers that can serve as more robust predictors of outcome. While clinical trials for targeted chemotherapy for bladder cancer have commenced, novel genetic and pharmacologic agents that can target pathway-specific molecules are currently under development. The next generation of clinical management for urothelial carcinoma will witness the use of multimarker panels for prognostic prediction and combination therapy directed at novel molecular targets for treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
RetractedWAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
The E2F transcription factor is a cellular target for the RB protein
Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M., & Nevins, J. R. (1991) · Cell · doi:10.1016/0092-8674(91)90557-f · Cited by 1,412
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,332
Epigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
The CpG dinucleotide and human genetic disease
Cooper, D. N., & Youssoufian, H. (1988) · Human Genetics · doi:10.1007/bf00278187 · Cited by 931
Basic fibroblast growth factor induces angiogenesis in vitro.
Montesano, R., Vassalli, J. D., Baird, A., Guillemin, R., & Orci, L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.19.7297 · Cited by 844
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer
Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S.-C., Nichols, P. W., Skinner, D. G., Jones, P. A., & Cote, R. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311903 · Cited by 783
Self-citationUncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
Waldman, T., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1996) · Nature · doi:10.1038/381713a0 · Cited by 728
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis
Vale, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13580-5 · Cited by 673
5-Methylcytosine as an Endogenous Mutagen in the Human LDL Receptor and p53 Genes
Rideout, W. M., Coetzee, G. A., Olumi, A. F., & Jones, P. A. (1990) · Science · doi:10.1126/science.1697983 · Cited by 640
Pepper, M. S., Ferrara, N., Orci, L., & Montesano, R. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91276-i · Cited by 615
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 597
Inhibition of DNA Methylation and Reactivation of Silenced Genes by Zebularine
Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S., Marquez, V. E., Jones, P. A., & Selker, E. U. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.399 · Cited by 535
Sarkis, A. S., Dalbagni, G. M., Cordon‐Cardo, C., Zhang, Z., Sheinfeld, J., Fair, W. R., Herr, H. W., & Reuter, V. E. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.53 · Cited by 517
Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) Tumors
Billerey, C., Chopin, D., Aubriot-Lorton, M.-H., Ricol, D., Gil Diez de Medina, S., Van Rhijn, B., Bralet, M.-P., Lefrere-Belda, M.-A., Lahaye, J.-B., Abbou, C. C., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64665-2 · Cited by 498
Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., & Folkman, J. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.5.356 · Cited by 464
Adnane, L., Trail, P. A., Taylor, I., & Wilhelm, S. M. (2006) · Methods in Enzymology · doi:10.1016/s0076-6879(05)07047-3 · Cited by 463
Esrig, D., Spruck, C., Nichols, P. W., Chaiwun, B., Steven, K. E., Groshen, S. G., Chen, S. C., Skinner, D. G., Jones, P. A., & Côté, R. J. (1993) · PubMed Central · Cited by 452
Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes
Kaminskas, E., Farrell, A., Abraham, S., Baird, A., Hsieh, L.-S., Lee, S.-L., Leighton, J. K., Patel, H., Rahman, A., Sridhara, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2135 · Cited by 423
Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zöchbauer‐Müller, S., Farinas, A. J., Vakar‐Lopez, F., Minna, J. D., Sagalowsky, A. I., et al. (2001) · PubMed · Cited by 422
Angiogenesis in Bladder Cancer: Relationship Between Microvessel Density and Tumor Prognosis
Bochner, B. H., Cote, R. J., Weidner, N., Groshen, S., Chen, S.-C., Skinner, D. G., & Nichols, P. W. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.21.1603 · Cited by 420
Self-citationThe expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model.
Sved, J., & Bird, A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4692 · Cited by 379
WINQUIST, E., KIRCHNER, T. S., SEGAL, R., CHIN, J., LUKKA, H., & on behalf of the GENITOURINARY CANCER DISEASE SITE GROUP OF CANCER CARE ONTARIO PROGRAM IN EVIDENCE-BASED CARE PRACTICE GUIDELINES INITIATIVE (2004) · Journal of Urology · doi:10.1097/01.ju.0000090967.08622.33 · Cited by 358
Signaling Networks That Link Cell Proliferation and Cell Fate
Sears, R. C., & Nevins, J. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100063200 · Cited by 336
p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer
Shariat, S. F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G. E., Benedict, W. F., & Lerner, S. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.118 · Cited by 327
Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Bochner, B. H., Esrig, D., Nichols, P. W., Taylor, C. R., Cote, R. J., Groshen, S., Dunn, M., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.3.219 · Cited by 319
Self-citationP53 as a prognostic marker for bladder cancer: a meta-analysis and review
Malats, N., Bustos, A., Nascimento, C. M., Fernandez, F., Rivas, M., Puente, D., Kogevinas, M., & Real, F. X. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70315-6 · Cited by 317
Catto, J. W. F., Azzouzi, A.-R., Rehman, I., Feeley, K. M., Cross, S. S., Amira, N., Fromont, G., Sibony, M., Cussenot, O., Meuth, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.163 · Cited by 316
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma
Kim, E. S., Serur, A., Huang, J., Manley, C. A., McCrudden, K. W., Frischer, J. S., Soffer, S. Z., Ring, L., New, T., Zabski, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398399 · Cited by 312
Effect of p21WAF1/CIP1 Expression on Tumor Progression in Bladder Cancer
Stein, J. P., Ginsberg, D. A., Grossfeld, G. D., Chatterjee, S. J., Esrig, D., Dickinson, M. G., Groshen, S., Taylor, C. R., Jones, P. A., Skinner, D. G., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1072 · Cited by 299
Self-citationIssa, J.-P. J., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G., & Kantarjian, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.981 · Cited by 288
Chan, M. W. Y., Chan, L. W., Tang, N. L. S., TONG, J. H. M., Lo, K. W., Lee, T., Cheung, H. Y., Wong, W. S., Chan, P. S. F., Lai, F. M., et al. (2002) · PubMed · Cited by 282
Bakkar, A., Wallerand, H., Radvanyi, F., Lahaye, J.-B., Pissard, S., Lecerf, L., Kouyoumdjian, J. C., Abbou, C. C., Pairon, J. ‐., Jaurand, M., et al. (2003) · PubMed · Cited by 270
p53 and treatment of bladder cancer
Cote, R. J., Esrig, D., Groshen, S., Jones, P. A., & Skinner, D. G. (1997) · Nature · doi:10.1038/385123b0 · Cited by 269
Self-citationCell cycle targets of Ras/Raf signalling
Kerkhoff, E., & Rapp, U. R. (1998) · Oncogene · doi:10.1038/sj.onc.1202185 · Cited by 260
Chatterjee, S. J., Datar, R., Youssefzadeh, D., George, B., Goebell, P. J., Stein, J. P., Young, L., Shi, S.-R., Gee, C., Groshen, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.174 · Cited by 254
Self-citationPRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
Knowles, M. A. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi310 · Cited by 248
Tornaletti, S., & Pfeifer, G. P. (1995) · PubMed · Cited by 247
Small-molecule cyclin-dependent kinase modulators
Senderowicz, A. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206954 · Cited by 236
van Rhijn, B. W. G., van der Kwast, T. H., Vis, A. N., Kirkels, W. J., Boevé, E. R., Jöbsis, A. C., & Zwarthoff, E. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2421 · Cited by 227
Crew, J. P., O'Brien, T., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D., & Harris, A. L. (1998) · The Journal of Urology · doi:10.1097/00005392-199811000-00090 · Cited by 225
Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., Radinsky, R., & Dinney, C. P. (2000) · PubMed · Cited by 225
Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer.
Inoue, K., Slaton, J. W., Kim, S. J., Perrotte, P., Eve, B. Y., Bar‐Eli, M., Radinsky, R., & Dinney, C. P. (2000) · PubMed · Cited by 222
Altered DNA methylation and genome instability: A new pathway to cancer?
Jones, P. A., & Gonzalgo, M. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2103 · Cited by 218
The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling
Dunn, K. L., Espino, P. S., Drobic, B., He, S., & Davie, J. R. (2005) · Biochemistry and Cell Biology · doi:10.1139/o04-121 · Cited by 218
McCawley, L. J., O'Brien, P., & Hudson, L. G. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199808)176:2<255::aid-jcp4>3.0.co;2-n · Cited by 215
Mutagenic and epigenetic effects of DNA methylation
Gonzalgo, M. L., & Jones, P. A. (1997) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(96)00047-6 · Cited by 213
Connecting proliferation and apoptosis in development and disease
Hipfner, D. R., & Cohen, S. M. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1491 · Cited by 193
Siu, L. L., Awada, A., Takimoto, C. H., Piccart, M., Schwartz, B., Giannaris, T., Lathia, C., Petrenciuc, O., & Moore, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1571 · Cited by 188
Detection of Bladder Cancer in Urine by a Tumor Suppressor Gene Hypermethylation Panel
Dulaimi, E., Uzzo, R. G., Greenberg, R. E., Al-Saleem, T., & Cairns, P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0127 · Cited by 188
Brown, N. S., Jones, A., Fujiyama, C., Harris, A. L., & Bicknell, R. (2000) · PubMed · Cited by 187
HER2 overexpression in muscle‐invasive urothelial carcinoma of the bladder: Prognostic implications
Krüger, S., Weitsch, G., Büttner, H., Matthiensen, A., Böhmer, T., Marquardt, T., Sayk, F., Feller, A. C., & Böhle, A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10731 · Cited by 176
Magewu, A. N., & Jones, P. A. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.4225 · Cited by 152
Anticancer therapy targeting the erbB family of receptor tyrosine kinases
Slichenmyer, W. J., & Fry, D. W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90284-2 · Cited by 143
(2002) · PubMed · Cited by 143
Serth, J., Kuczyk, M., Bokemeyer, C., Hervatin, C., Nafe, R., Tan, H. K., & Udo Jonas, A. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.41 · Cited by 142
Kuball, J. H. E., Wen, S. F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D. C., Grace, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.957 · Cited by 135
Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee, M., Kim, H. Y., Byun, D.-S., Lee, S., Lee, C. H., Kim, J. I., Chang, S., & Chi, S. G. (2001) · PubMed · Cited by 134
Rational therapeutic intervention in cancer: kinases as drug targets
Sawyers, C. L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00273-8 · Cited by 129
Novel Small Molecule Cyclin-Dependent Kinases Modulators in Human Clinical Trials
Senderowicz, A. M. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.207 · Cited by 121
Cronauer, M. V., Schulz, W. A., Seifert, H., Ackermann, R., & Burchardt, M. (2003) · European Urology · doi:10.1016/s0302-2838(03)00005-8 · Cited by 110
Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens.
Dowell, S. P., Wilson, P., Derias, N. W., Lane, D. P., & Hall, P. A. (1994) · PubMed · Cited by 110
Rieger‐Christ, K., Mourtzinos, A. P., Lee, P. J., Zagha, R. M., Cain, J. E., Silverman, M. L., Libertino, J. A., & Summerhayes, I. C. (2003) · Cancer · doi:10.1002/cncr.11536 · Cited by 109
Meyerhardt, J. A., Zhu, A. X., Enzinger, P. C., Ryan, D. P., Clark, J. W., Kulke, M. H., Earle, C. C., Vincitore, M., Michelini, A. L., Sheehan, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3728 · Cited by 103
Chan, M. W. Y., Chan, L. W., Tang, N. L. S., Lo, K. W., TONG, J. H. M., Chan, A. W. H., Cheung, H. Y., Wong, W. S., Chan, P. S. F., Lai, F. M., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10971 · Cited by 102
Berggren, P., Kumar, R., Sakano, S., Hemminki, L., Wada, T., Steineck, G., Adolfsson, J., Larsson, P., Norming, U., Wijkström, H., et al. (2003) · PubMed · Cited by 101
Inhibitors of the mammalian target of rapamycin
Dancey, J. E. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.3.313 · Cited by 99
Holleran, J. L., Parise, R. A., Joseph, E., Eiseman, J. L., Covey, J. M., Glaze, E. R., Lyubimov, A. V., Chen, Y.-F., D’Argenio, D. Z., & Egorin, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2406 · Cited by 97
p53 Mutations and Prognosis in Bladder Tumors
Uchida, Τ., Wada, C., Ishida, H., Wang, C., Egawa, S., Yokoyama, E., Kameya, T., & Koshiba, K. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67517-7 · Cited by 96
Bergstralh, D. T., & Ting, J. P. ‐. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.01.004 · Cited by 94
Davis, A. J., Gelmon, K. A., Siu, L. L., Moore, M. J., Britten, C. D., Mistry, N., Klamut, H. J., D’Aloisio, S., MacLean, M., Wainman, N., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1022976528441 · Cited by 92
p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer
Kawamoto, K., Enokida, H., Gotanda, T., Kubo, H., Nishiyama, K., Kawahara, M., & Nakagawa, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.072 · Cited by 92
Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin, M., Ariel, I., Miao, H. Q., Nagler, A., Pines, M., de-Groot, N., Hochberg, A., & Vlodavsky, I. (1999) · PubMed · Cited by 91
Yates, D. R., Rehman, I., Meuth, M., Cross, S. S., Hamdy, F. C., & Catto, J. W. F. (2005) · Oncogene · doi:10.1038/sj.onc.1209209 · Cited by 90
Dominguez-Escrig, J. L., Kelly, J. D., Neal, D. E., King, S. M., & Davies, B. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0034 · Cited by 88
Retinoblastoma gene mutations in primary human bladder cancer
Miyamoto, H., Shuin, T., Torigoe, S., Iwasaki, Y., & Kubota, Y. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.160 · Cited by 87
Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression
OXFORD, G., & THEODORESCU, D. (2003) · Journal of Urology · doi:10.1097/01.ju.0000088670.02905.78 · Cited by 86
Luu, Y., Bush, J., Cheung, K. J., & Li, G. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5526 · Cited by 75
Mitra, A. P., Almal, A. A., George, B., Fry, D. W., Lenehan, P. F., Pagliarulo, V., Côté, R. J., Datar, R. H., & Worzel, W. P. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-159 · Cited by 75
Self-citationAngiogenesis in bladder cancer—prognostic marker and target for future therapy
Streeter, E. H., & Harris, A. L. (2002) · Surgical Oncology · doi:10.1016/s0960-7404(02)00013-0 · Cited by 67
Genetic Alterations of p16INK4a and p14ARF Genes in Human Bladder Cancer
Chang, L., YEH, W.-T., Yang, S., Wu, W., & Huang, C. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000067626.37837.3e · Cited by 66
Schnier, J. B., Nishi, K., Goodrich, D. W., & Bradbury, E. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5941 · Cited by 60
Molecular staging of bladder cancer
Mitra, A. P., Datar, R. H., & Côté, R. J. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05557.x · Cited by 59
Self-citationLipponen, P. (1995) · The Journal of Pathology · doi:10.1002/path.1711750208 · Cited by 59
Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein.
Xu, H., Xu, K., Zhou, Y., Li, J. L. Y., Benedict, W. F., & Hu, S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9837 · Cited by 58
Demma, M. J., Wong, S., Maxwell, E., & Dasmahapatra, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401854200 · Cited by 58
Molecular Biology of Bladder Cancer: Prognostic and Clinical Implications
Mitra, A. P., Lin, H., Datar, R. H., & Côté, R. J. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.020 · Cited by 52
Self-citationGazzaniga, P., Gandini, O., Gradilone, A., Silvestri, I., Giuliani, L., Magnanti, M., Gallucci, M., Saccani, G., Frati, L., & Aglianò, A. M. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.6.1123 · Cited by 49
Inoue, K., Chikazawa, M., Fukata, S., Yoshikawa, C., & Shuin, T. (2002) · PubMed · Cited by 49
Pagliaro, L. C., Keyhani, A., Liu, B., Perrotte, P., Wilson, D., & Dinney, C. P. (2003) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(03)00032-2 · Cited by 44
Zhang, X., Multani, A. S., Zhou, J., Shay, J. W., McConkey, D. J., Dong, L., Kim, C.-S., Rosser, C. J., Pathak, S., & Benedict, W. F. (2003) · PubMed · Cited by 44
Inhibition of Orthotopic Human Bladder Tumor Growth by Lentiviral Gene Transfer of Endostatin
Kikuchi, E., Menéndez, S., Ohori, M., Cordon‐Cardo, C., Kasahara, N., & Bochner, B. H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0099 · Cited by 36
c-myc oncoprotein levels in bladder cancer
Masters, J. R. W., Vesey, S. G., Munn, C. F., et al. (1988) · Urological Research · doi:10.1007/bf00256039 · Cited by 33
Lübbert, M., Daskalakis, M., Kunzmann, R., Engelhardt, M. M., Guo, Y., & Wijermans, P. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.04.002 · Cited by 33
Kunze, E., von Bonin, F., Werner, C., Wendt, M., & Schlott, T. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.1.3 · Cited by 33
Tanner, S., & Barberis, A. (2004) · Journal of Negative Results in BioMedicine · doi:10.1186/1477-5751-3-5 · Cited by 33
INTERLEUKIN-8 (IL-8) EXPRESSION REGULATES TUMORIGENICITY AND METASTASIS IN HUMAN BLADDER CANCER
Inoue, K., Slaton, J. W., Perrotte, P., Eve, B. Y., & Dinney, C. P. (1999) · The Journal of Urology · doi:10.1097/00005392-199904010-00483 · Cited by 24
Biomarker profiling for cancer diagnosis, prognosis and therapeutic management.
Mitra, A. P., Lin, H. C., Côté, R. J., & Datar, R. H. (2005) · PubMed · Cited by 23
Self-citationMutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis
Ho, C. K., & Li, G. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06810.x · Cited by 22
The Anti-Angiogenic Activity of Human Endostatin Inhibits Bladder Cancer Growth and Its Mechanism
Du, Z., & Hou, S.-K. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000091879.18156.22 · Cited by 22
Bevacizumab and erlotinib show promise for kidney cancer
Lindsey, H. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70521-0 · Cited by 10
Cited by
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Identification of novel microRNA targets based on microRNA signatures in bladder cancer
Ichimi, T., Enokida, H., Okuno, Y., Kunimoto, R., Chiyomaru, T., Kawamoto, K., Kawahara, K., Toki, K., Kawakami, K., Nishiyama, K., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24390 · Cited by 404
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development
Knapp, D. W., Ramos-Vara, J. A., Moore, G. E., Dhawan, D., Bonney, P. L., & Young, K. E. (2014) · ILAR Journal · doi:10.1093/ilar/ilu018 · Cited by 284
Metadata
- Authors
- Mitra, A. P., Datar, R. H., & Cote, R. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-12-10
- Volume
- 24
- Issue
- 35
- Pages
- 5552-5564
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2122500907
- Cited by
- 284
- References
- 115
- FWCI
- 21.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.